In April 2022, I pointed out that one of the nerdy, but very important, parts of the FDA tobacco product regulatory process is the list of “Hazardous and Potentially Hazardous Compounds” (HPHC) list that FDA released in 2012. This list contains 93 bad chemicals — mostly carcinogens — that FDA identified as important when assessingContinue reading “FDA should finalize its updated list of Harmful and Potentially Harmful Constituents by December 2023”
Category Archives: FDA
FDA (and others) should integrate the relationship between cannabis and tobacco use
My UCSF colleagues and I submitted a public comment to the FDA Center for Tobacco Products regarding its upcoming strategic plan urging FDA to more strongly integrate the crossover between tobacco and cannabis use into its planning. While FDA does not (yet) have jurisdiction over cannabis, there is no question that growing cannabis use hasContinue reading “FDA (and others) should integrate the relationship between cannabis and tobacco use”
FDA should prioritize direct measures of health and behavioral effects over indirect measures or assumptions in making regulatory decisions
Last week I posted by oral testimony to the FDA listening session for developing its strategic plan, “FDA CTP should prioritize direct epidemiological population measures of health and behavior over indirect measures or assumptions.” My UCSF colleagues and I also subsequently submitted a written public comment amplifying the points in the oral testimony, including citations forContinue reading “FDA should prioritize direct measures of health and behavioral effects over indirect measures or assumptions in making regulatory decisions”
FDA CTP should prioritize direct epidemiological population measures of health and behavior over indirect measures or assumptions.
On August 22, 2023 the FDA Center for Tobacco Products held a listening session to gather public input to help it prepare it’s strategic plan. Here is what I said: My name is Stanton Glantz. I am a retired UCSF Professor of Medicine and served as principal investigator of the UCSF TCORS until I retired. Continue reading “FDA CTP should prioritize direct epidemiological population measures of health and behavior over indirect measures or assumptions.”
Juul 2: Facebook merges with a drug cartel
E-cigarette company Juul has applied to the FDA for permission to market its Juul 2 e-cigarette, which allows two-way communication with the device, nominally to prevent youth use. Juul reports that the Juul 2 pairs with a phone app to verify a user’s age: “The user must upload their photo ID and take a real-timeContinue reading “Juul 2: Facebook merges with a drug cartel”
UC publishes oral history of Stanton Glantz: Putting Cardiovascular, Epidemiological, Economic, Political, and Policy Research into Action at UC San Francisco and Beyond
Today the Oral History Center at the University of California Bancroft Library published an oral history of my career, which is freely available to all. Beginning in elementary school in Cleveland, Ohio, the history follows me through college and gradual school. It discusses my work to develop the emergency protocols for the Apollo 5 missionContinue reading “UC publishes oral history of Stanton Glantz: Putting Cardiovascular, Epidemiological, Economic, Political, and Policy Research into Action at UC San Francisco and Beyond”
FDA denies myblu menthol e-cig
FDA has denied a marketing order for Fontem’s myblu menthol e-cigarette. This is FDA’s second denial of a marketing order for a menthol e-cigarette, following its denial of RJR’s Vuse Solo menthol and other menthol e-cigarettes. With this decision, FDA continues to move away from its previous permissive policy toward menthol e-cigarettes, which appears toContinue reading “FDA denies myblu menthol e-cig”
More evidence that England’s (and Canada and US FDA) enthusiastic approach to e-cigarettes is a disaster
In April 2023, David Hammond and colleagues published trends in high school use of e-cigarettes, cigarettes and other tobacco products in three e-cigarette-countries with policies to promote adult use of e-cigarettes for harm reduction: England, Canada and the US. In the International Tobacco Control Policy Evaluation Project (ITC) Youth Tobacco and Vaping Survey England, whichContinue reading “More evidence that England’s (and Canada and US FDA) enthusiastic approach to e-cigarettes is a disaster”
E-cig market shifts to keep growing rapidly as it adapts to loopholes the federal government leaves open
Last week, the CDC Morbidity and Mortality Weekly report published “E-cigarette Unit Sales by Product and Flavor Type, and Top-Selling Brands, United States, 2020–2022” that reported rapid growth in e-cigarette sales: from January, 2020 to December, 2022, e-cigarette sales increased by 46.6%. (These figures are based on checkout bar code scanner data from retailers andContinue reading “E-cig market shifts to keep growing rapidly as it adapts to loopholes the federal government leaves open”
Who’s behind the expensive campaign to ban Chinese disposable e-cigs?
On June 21, 2023 Consumer Action for a Strong Economy ran this full page ad in the San Francisco Chronicle urging the public to demand that the FDA “get illicit disposable vapes in kid-enticing flavors from China off American store shelves.” On the webpage linked to this ad, Consumer Action for a Strong Economy (CASE)Continue reading “Who’s behind the expensive campaign to ban Chinese disposable e-cigs?”
Stanton Glantz blog 